WO2007013290A1 - Agent analgésique anti-inflammatoire - Google Patents

Agent analgésique anti-inflammatoire Download PDF

Info

Publication number
WO2007013290A1
WO2007013290A1 PCT/JP2006/313718 JP2006313718W WO2007013290A1 WO 2007013290 A1 WO2007013290 A1 WO 2007013290A1 JP 2006313718 W JP2006313718 W JP 2006313718W WO 2007013290 A1 WO2007013290 A1 WO 2007013290A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
inflammatory
pharmaceutical composition
mouth
analgesic
Prior art date
Application number
PCT/JP2006/313718
Other languages
English (en)
Japanese (ja)
Inventor
Akiyoshi Oohira
Norikazu Yamaguchi
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Priority to JP2007528401A priority Critical patent/JPWO2007013290A1/ja
Publication of WO2007013290A1 publication Critical patent/WO2007013290A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical composition for anti-inflammatory analgesia characterized by containing a calpe mouth-toum salt.
  • the present invention also relates to the use of an anti-inflammatory analgesic agent for calc mouth-um salt, and pain comprising administering an effective amount of carpronium salt to a patient having pain and Z or inflammation. And methods for treating and preventing Z or inflammation.
  • Non-patent document 1 Drugs containing calp mouth-um ((3-methoxycarbopropyl) trimethylammo-muchloride) are effective for chronic gastritis and flaccid constipation with decreased gastrointestinal function as internal medicine
  • Non-patent document 1 is also used as a topical medicine for alopecia areata, malignant alopecia, diffuse alopecia, erosive alopecia, juvenile alopecia and symptomatic alopecia and hair growth prevention and hair growth promotion, and Efficacy against dry seborrhea and common vitiligo (see Non-Patent Document 2 and Patent Document 1) is known.
  • Salt-calp mouth-um is a parasympathomimetic drug, and unlike acetylcholine, it is stable to acid that is not easily affected by cholinesterase, so it directly touches the stomach wall by oral administration and has a cholinergic effect. It acts selectively on the gastrointestinal tract, promotes the movement of the stomach and intestinal contents, corrects the decrease in gastric acid secretion, and improves the gastrointestinal function.
  • salty calp mouth-um has a local vasodilatory effect about 10 times that of acetylcholine, and has a strong and sustained dilation effect on local blood vessels that are not easily affected by cholinesterase, and is a hair follicle. It is known that there is a function improving action against.
  • Carp chloride-um has a terminal ester moiety of acetylcholine (one OCOCH) reversed.
  • the structure (one COOCH) has excellent skin permeability and affects the wide circulation system.
  • Non-Patent Document 3 It has also been reported to promote oxygen supply to local tissues such as hair roots because it acts on the microcirculatory system and exhibits local blood vessel dilation.
  • Other actions of Calp Mouth-um include stress-induced hair loss, stress stiff shoulders, stress-induced microcirculatory dysfunction-improving agents (see Patent Document 2), and stress-related Anti-stress agent for preventing or improving rough skin (see Patent Document 3), housewife eczema that includes contact dermatitis due to detergent, etc., progressive palmokeratosis, radiant eczema (cracking, redhead)
  • Eczema 'dermatitis group consisting of dermatitis and other skin disease treatment agents such as frostbite (see Patent Document 4) have also been reported!
  • Inflammation is a biological reaction when a living body is damaged by the invasion or impact of pathogenic microorganisms, and exhibits symptoms such as redness, heat, edema, and pain. These symptoms are due to local vasodilatation and contraction, increased vascular permeability, increased blood flow, and sensitization of perivascular pain receptors.
  • the onset mechanism is thought to be prostaglandin production. It has been. Therefore, aspirin, ibupofen, indomethacin, piroxicam, mefenamic acid, and the like, which inhibit the prostaglandin-producing enzyme cycloxinase, are known and widely used as non-steroidal anti-inflammatory agents.
  • Patent Document 1 Japanese Patent Publication No. 42-5680
  • Patent Document 2 JP 2002-265363 A Patent Document 3: Japanese Patent Laid-Open No. 2002-265361
  • Patent Document 4 Japanese Patent Publication No. 61-30644
  • Non-Patent Document 1 Shio Carpronium: Japan Pharmaceuticals, Japan Pharmaceutical Information Center, 28th edition, Jiho Co., Tokyo (2005)
  • Non-Patent Document 2 Carpronium Chloride: Japan Pharmaceutical Collection, Japan Pharmaceutical Information Center, 28th Edition, Jiho Co., Tokyo (2005)
  • Non-Patent Document 3 Chiyoharu Okubo, “Nippon Yakuhin Magazine”, Vol. 91, pp. 245-253, 1988 Disclosure of the Invention
  • An object of the present invention is to provide an anti-inflammatory analgesic having excellent safety and having an excellent anti-inflammatory action and Z or analgesic action.
  • the present invention relates to a pharmaceutical composition for anti-inflammatory analgesia comprising a carp mouth-um salt ((3-methoxycarbo-propyl) trimethylam-um salt) as an active ingredient, that is, an anti-inflammatory analgesic. Is to provide.
  • a carp mouth-um salt ((3-methoxycarbo-propyl) trimethylam-um salt) as an active ingredient, that is, an anti-inflammatory analgesic.
  • the present invention also relates to the use of a calpe mouth-um salt for producing an anti-inflammatory analgesic.
  • the present invention also relates to a method for improving inflammation and Z or pain comprising administering an effective amount of carpronium salt to a patient having inflammation and Z or pain, and treating and preventing these symptoms.
  • the present invention contains a calpe mouth-um salt as an anti-inflammatory component and Z or an analgesic component. It is related with the pharmaceutical composition formed by this, Preferably a skin external preparation.
  • a pharmaceutical composition for anti-inflammatory analgesia comprising calpe mouth-um salt as an active ingredient.
  • Strength An anti-inflammatory analgesic comprising rupro-um salt.
  • the anti-inflammatory analgesic pharmaceutical composition further comprises another anti-inflammatory analgesic in addition to carpronium salt as an anti-inflammatory analgesic component.
  • a pharmaceutical composition for inflammatory analgesia A pharmaceutical composition for inflammatory analgesia.
  • the pharmaceutical composition for anti-inflammatory analgesia further contains another anti-inflammatory analgesic in addition to the calpe mouth-um salt as an effective component for anti-inflammatory analgesia.
  • anti-inflammatory analgesic according to (1) or (2), wherein the anti-inflammatory analgesic further contains another anti-inflammatory analgesic in addition to the carpronium salt as an anti-inflammatory analgesic component.
  • composition for anti-inflammatory analgesia according to any one of (1) to (4), wherein the pharmaceutical composition for anti-inflammatory analgesia is a parenteral preparation.
  • composition for anti-inflammatory analgesia according to (5), wherein the parenteral preparation is a transdermal administration preparation.
  • the anti-inflammatory analgesic according to (5), wherein the parenteral preparation is a preparation for transdermal administration.
  • composition for anti-inflammatory analgesia according to any one of (1) to (4), wherein the pharmaceutical composition for anti-inflammatory analgesia is an oral preparation.
  • a pharmaceutical composition for anti-inflammation comprising calpe mouth-um salt as an active ingredient.
  • Calp Anti-inflammatory agent containing mouth-um salt.
  • Carpronium salt power The anti-inflammatory pharmaceutical composition according to (8) above, which is salt carpronium.
  • Calp mouth-um salt power The anti-inflammatory according to (8) above, which is a salt mouth calm mouth-um Agent.
  • composition for anti-inflammatory
  • the composition further contains another anti-inflammatory analgesic agent for anti-inflammatory as described in (8) or (9) above.
  • Medicine composition The anti-inflammatory pharmaceutical composition according to (8) or (9), wherein the anti-inflammatory pharmaceutical composition further contains another anti-inflammatory analgesic agent in addition to the carpronium salt as an active ingredient for anti-inflammatory.
  • the anti-inflammatory pharmaceutical composition according to (12), wherein the parenteral preparation is a transdermal administration preparation.
  • the anti-inflammatory agent according to (12), wherein the parenteral preparation is a preparation for transdermal administration.
  • a pharmaceutical composition for analgesia comprising calpe mouth-um salt as an active ingredient.
  • Carpronium salt power The analgesic pharmaceutical composition according to the above (15), which is a salty carpronium.
  • Calp mouth-to-mouth salt power The analgesic according to the above (15), which is a salt mouth-to-mouth mouth mouth.
  • analgesic composition according to the above (15) or (16), wherein the analgesic pharmaceutical composition further contains another anti-inflammatory analgesic agent in addition to the calpe mouth-um salt as an analgesic component.
  • Pharmaceutical composition The analgesic medicament according to (15) or (16) above, wherein the analgesic pharmaceutical composition further contains another anti-inflammatory analgesic agent in addition to carpronium salt as an active ingredient for analgesia.
  • Composition Composition.
  • a pharmaceutical composition for anti-inflammatory analgesia comprising an active ingredient for anti-inflammatory action and a calp-um salt as an active ingredient for Z or analgesic action, and a pharmaceutically acceptable carrier object.
  • a pharmaceutical composition comprising a calpe mouth-um salt as an active ingredient for anti-inflammatory analgesia. More specifically, an active ingredient for anti-inflammatory action, and carpronium salt as an active ingredient for Z or analgesic action, and a thread for treating or preventing inflammation and Z or pain comprising a pharmaceutically acceptable carrier And adult.
  • Carpronium salt power The pharmaceutical composition according to the above (22) or (23), which is carpronium chloride.
  • composition power The method according to (27) or (28), wherein the pharmaceutical composition further comprises another anti-inflammatory analgesic agent in addition to carpronium salt as an anti-inflammatory analgesic component.
  • a method for treating / preventing inflammation comprising administering an effective amount of carpronium salt to a patient having inflammation.
  • a method for treating and / or preventing inflammation comprising administering a pharmaceutical composition comprising an effective amount of carpronium salt to a patient having inflammation.
  • composition further comprises another anti-inflammatory analgesic in addition to the calpe mouth-um salt as an anti-inflammatory component.
  • pharmaceutical composition is a pharmaceutical composition further containing another anti-inflammatory analgesic in addition to carpronium salt as an active ingredient for anti-inflammation.
  • the pharmaceutical composition comprising an effective amount of a calpe mouth-um salt is an oral preparation.
  • a method for treating and / or preventing pain comprising administering an effective amount of carpronium salt to a patient having pain.
  • Contains effective amount of carpronium salt for patients with pain A method for treating and / or preventing pain comprising administering a pharmaceutical composition.
  • Carpronium salt power The method according to the above (39), which is carpronium chloride.
  • composition strength The method according to (39) or (40) above, which is a pharmaceutical composition further containing another anti-inflammatory analgesic agent in addition to the calpe mouth-um salt as an analgesic component.
  • Pharmaceutical composition The method according to (39) or (40) above, which is a pharmaceutical composition further containing another anti-inflammatory analgesic agent in addition to carpronium salt as an active ingredient for analgesia.
  • anti-inflammatory analgesic is an anti-inflammatory analgesic containing another anti-inflammatory analgesic in addition to carpronium salt as an anti-inflammatory analgesic component (use 0 )
  • the anti-inflammatory analgesic is an anti-inflammatory analgesic containing the other anti-inflammatory analgesic in addition to carpronium salt as an active ingredient for anti-inflammatory analgesia, as described in the above (45) or (46) Use.
  • anti-inflammatory agents can also be used as other anti-inflammatory agents.
  • analgesic is an analgesic further containing another anti-inflammatory analgesic in addition to the carpronium salt as an analgesic component.
  • analgesic is an analgesic further containing another anti-inflammatory analgesic in addition to the calpe mouth-um salt as an active ingredient for analgesia. .
  • the calp mouth-mud salt used in the present invention is a calp mouth-um ((3-methoxycarbo-propyl) trimethylammonium) force cationic ammonium ion
  • calp mouth-um ((3-methoxycarbo-propyl) trimethylammonium) force cationic ammonium ion
  • examples thereof include compounds having an anion as a counter ion of the ammonium ion.
  • examples of such anions include inorganic anions such as chlorine ions, bromine ions, iodine ions, nitrate ions, sulfate ions, phosphate ions, and carbonate ions, and organic anions such as citrate ions, oxalate ions, and lactate ions. And ions.
  • Preferable anions of the calp mouth salt of the present invention include halogen ions such as chlorine ions, and anions that also induce organic acid power such as citrate ions.
  • halogen ions such as chlorine ions
  • organic acid power such as citrate ions.
  • anion Includes chloride ions, that is, salt-calp mouthpieces.
  • the pharmaceutical composition for anti-inflammatory analgesia of the present invention is a so-called anti-inflammatory analgesic and is characterized by containing the carp mouth-mum salt of the present invention and a pharmaceutically acceptable carrier as active ingredients.
  • the “anti-inflammatory analgesia” in the present invention has an anti-inflammatory action and an analgesic action, and can treat or prevent inflammation and pain.
  • the “anti-inflammatory analgesia” of the present invention acts on inflammation and pain, but acts on inflammation and pain individually as well as on inflammation and pain simultaneously. Cases are also included. Therefore, the “anti-inflammatory analgesic” of the present invention may be used to act on both inflammation and pain at the same time, or acts individually on each symptom on inflammation or pain. It also includes things that are intended to be made. In this sense, in the meaning of the present invention, both anti-inflammation and pain are included, including both the case where both act on inflammation and pain simultaneously and the case where each acts separately.
  • the terms “Z or analgesia”, “inflammation and Z or pain”, “anti-inflammatory analgesia” are used.
  • the pharmaceutical composition of the present invention contains the carp mouth-mum salt of the present invention as an active ingredient as an active ingredient for anti-inflammatory analgesia (anti-inflammatory and Z or analgesic ingredient), and other active ingredients for pharmaceutical use. And a pharmaceutically acceptable carrier.
  • active pharmaceutical ingredients include anti-inflammatory agents, anti-inflammatory analgesics, analgesics and the like.
  • preferable pharmaceutical active ingredients include, but are not limited to, for example, non-steroidal anti-inflammatory analgesics such as indomethacin.
  • the compounding amount of carpronium salt in the anti-inflammatory analgesic pharmaceutical composition (anti-inflammatory and Z or analgesic) or pharmaceutical composition of the present invention is not particularly limited, but is 0.01 to
  • the anti-inflammatory analgesic of the present invention can be administered in a misaligned form of oral administration or parenteral administration.
  • the calpe mouth-mud salt of the present invention is known to have excellent skin permeability, and can also be administered transdermally as an external preparation for skin.
  • Examples of the dosage form of the anti-inflammatory analgesic composition or pharmaceutical composition of the present invention include oral preparations and parenteral preparations.
  • Examples of parenteral preparations include skin preparations, eye drops, embedding agents and the like, and skin preparations are particularly preferable.
  • oral preparations examples include tablets, granules, capsules, drinks, jelly preparations and the like.
  • parenteral preparations include patches such as creams, gels, solutions, patches, and plasters.
  • Oral preparations may be prepared using commonly used excipients, binders, disintegrants, disintegration inhibitors, absorption enhancers, humectants, adsorbents, lubricants, and the like.
  • excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, and kainate, water, ethanol, propanol, simple syrup, glucose solution, starch solution, shellac, potassium phosphate
  • Binders such as dry starch, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, monoglyceride stearate, starch, lactose, etc., white sugar, stearin, Decay inhibitors such as cocoa butter, hydrogenated oil, quaternary ammonia base, absorption promoters such as sodium lauryl sulfate, hum
  • a parenteral preparation may be prepared using base components such as a thickener, an emulsifier, a neutralizer, a preservative, a stabilizer, a wetting agent, water, and fats and the like that are usually used.
  • base components such as a thickener, an emulsifier, a neutralizer, a preservative, a stabilizer, a wetting agent, water, and fats and the like that are usually used.
  • thickeners such as carboxyvinyl polymer, hydroxyethyl cellulose, carrageenan, sodium alginate, xanthan gum
  • emulsifiers such as glycerin fatty acid ester, propylene glycol fatty acid ester, alkyl glyceryl ether, polyoxyethylene sorbitol fatty acid ester, polysorbate
  • Neutralizing agents such as inorganic acids such as hydrochloric acid, alkali hydroxides such as sodium hydroxide and lithium hydroxide, amine
  • the action of the analgesic in the anti-inflammatory analgesic of the present invention can be used for any of nociceptive pain, neuropathic pain, psychogenic pain and the like.
  • Nociceptive pain is pain that occurs when a living tissue is damaged, and includes pain after surgery, pain caused by cancer, pain caused by inflammation, and the like.
  • Neuropathic pain is pain caused by abnormalities in the nerve, spinal cord, and brain, and includes, for example, phantom limb pain, postherpetic neuralgia, reflex sympathetic dystrophy, causalgi and the like.
  • Psychogenic pain is pain associated with psychological disorders and includes pain that does not have a physical cause.
  • the anti-inflammatory analgesic of the present invention As the action of the analgesic in the anti-inflammatory analgesic of the present invention, it is particularly preferable to use it for pain caused by inflammation, which is preferably used for nociceptive pain. Furthermore, the anti-inflammatory analgesic of the present invention was confirmed to have an excellent anti-inflammatory action by a force-ragenin foot edema test described later.
  • the force lagenin paw edema test has been a famous test method in the history of indomethacin development, and Winter et al. Have shown that drugs that suppress force lagenin paw edema are present in human rheumatism. It is said that it has been empirically known to have an effect and has screened many drugs using this method.
  • the drug screened by the force ragenin paw edema test method has an anti-inflammatory action against various inflammations including rheumatism.
  • anti-inflammation refers to the suppression of biological reactions caused by the invasion or impact of pathogenic microorganisms. Specifically, it is not only redness, heat and edema that occurs at the inflamed site, but also chills associated with infection. It refers to the suppression of fever and nerve stimulation that occurs at the site of inflammation.
  • the anti-inflammatory action in the anti-inflammatory analgesic of the present invention includes effective actions against these various inflammations.
  • the anti-inflammatory analgesic agent of the present application has anti-inflammatory action and Z or analgesic action, and each action can be used alone as an anti-inflammatory or analgesic that can only be used as an anti-inflammatory analgesic. You can also
  • the dose of the calpe mouth-um salt in the present invention includes a target disease and a patient symptom. It varies depending on the severity, age of the patient, complications, etc., and also varies depending on the administration route, etc. Usually 0.01 mg to 2000 mg per adult, preferably 0.1 mg to 1500 mg, The dose is preferably 1 mg to 500 mg, which can be administered orally, intravenously, intramuscularly, rectally or transdermally.
  • calpe mouth-um salt has anti-inflammatory action and Z or analgesic action.
  • a novel pharmaceutical composition for anti-inflammatory analgesia as an active ingredient is provided.
  • a pharmaceutical composition containing a calpe mouth-um salt as an active ingredient is effective for the treatment or prevention of inflammation and pain. Therefore, the present invention provides a method for treating and preventing inflammation and Z or pain, comprising administering an effective amount of carpronium salt to a patient having inflammation and Z or pain.
  • This method of the present invention is generally used in patients with inflammation and Z or pain as carpronium salt according to the patient's symptoms, usually 0.01 mg to 2000 mg per adult, preferably 0.1 mg to
  • the above-mentioned preparation containing 1500 mg, more preferably 1 mg to 500 mg, is administered by a method such as oral administration, intravenous administration, intramuscular administration, rectal administration or transdermal administration. .
  • the present invention also provides the use of a calp mouth-um salt for producing an anti-inflammatory analgesic.
  • a calp mouth-um salt for producing an anti-inflammatory analgesic.
  • a new anti-inflammatory analgesic for improving inflammation and pain, a method of treatment or prevention using the anti-inflammatory analgesic, and use of carpronium salt for producing the anti-inflammatory analgesic (Use) can be provided.
  • Calp mouth-um salt used as an active ingredient of the anti-inflammatory analgesic of the present invention is highly safe and excellent in skin permeability to the gastrointestinal tract which is not easily affected by cholinesterase.
  • the present invention provides an anti-inflammatory analgesic that is highly safe without causing gastrointestinal disorders, a method for treating and preventing the same, and a use for producing the anti-inflammatory analgesic.
  • FIG. 1 shows that when the carpronium salt of the present invention is applied 3 hours after the onset of pain, the pain threshold before the onset of pain is 100% and the pain threshold at each time after the onset of pain is expressed as a percentage. It is a graph which shows the converted rate of change.
  • FIG. 2 shows 100% of the pain threshold before the onset of pain when the carpronium salt of the present invention (white triangle mark) and indomethacin (black circle mark) were applied 3 hours later, respectively.
  • FIG. 6 is a graph showing the rate of change in which the pain threshold value for each hour after pain induction is converted into a percentage.
  • Fig. 3 is a graph showing the rate of inhibition of the area under the time-edema volume curve (AUC) when each concentration of the calp mouth-mum salt of the present invention was applied 30 minutes before the onset of inflammation. It is.
  • Fig. 4 is a graph showing the change in edema volume when the carpronium salt of the present invention (black circle mark) and indomethacin (white triangle mark) are applied 30 minutes before the onset of inflammation, respectively. is there.
  • Fig. 5 is a graph showing changes in edema volume when the carpronium salt of the present invention (black circle mark) and indomethacin (white triangle mark) are applied 30 minutes before the onset of inflammation, respectively. is there.
  • Fig. 6 is a graph showing the results of measuring the analgesic effect when the salted calp mouthrum of the present invention was orally administered.
  • the white circles indicate the case where only control purified water was administered, and the black circles, black triangles, and black squares indicate that 30 mgZkg, 60 mgZkg, or 120 mgZkg of salted calp mouth was administered, respectively.
  • FIG. 7 is a graph showing the results of measuring the anti-inflammatory effect when the salted calp mouthrum of the present invention was orally administered. Open circles indicate the case where only control purified water was administered, and filled circles indicate the case where 120 mgZkg of salted calp mouth was administered.
  • FIG. 8 shows the anti-inflammatory effect of oral administration of the salted calp mouth-mums of the present invention until 1 hour after the onset of inflammation (white circle in FIG. 8) and 1 hour later.
  • 9 is a graph showing the results of calculating and evaluating the area under the time-one edema volume curve (AUC) from 1 to 5 hours (black circle in FIG. 8).
  • Example 1 A 5-week-old Wistar male rat was used to measure the pain threshold of the right hind leg before pain induction by the random cellit method. Subsequently, 0.1 mL of 20% beer yeast solution suspended in physiological saline was subcutaneously administered to the right hind footpad of the animal to induce pain, and the pain threshold was measured over time. The test substance was dissolved in a 7: 3 mixture of isopropanol and water and applied 3 hours after the onset of pain. The action of the test substance was evaluated as a percentage by converting the pain threshold value for each hour after the pain was induced into 100% as the pain threshold before the pain was induced. The analgesic effects of 2, 4 and 4% were examined. The results are shown in Fig. 1.
  • the horizontal axis in Fig. 1 shows the time (time) of pain-inducing force, and the vertical axis shows the rate of change (%) with the pain threshold before pain induction being 100%.
  • the white circle mark ( ⁇ ) in Fig. 1 indicates the case of no application, the black circle mark ( ⁇ ) indicates the case of 1% salty calp mouth, and the white triangle mark ( ⁇ ) indicates 2% salty calp. The case of mouth-um is shown, and the black triangle mark ( ⁇ ) shows the case of 4% salty-calpronium.
  • the pain threshold which was lowered 3 hours after the onset of pain, was improved depending on the dose of salty calp mouth-mud, and the submaximum concentration of analgesic action (almost maximum response to analgesic action). was 2%.
  • FIG. 2 The horizontal axis in FIG. 2 represents the time (time) from the onset of pain, and the vertical axis represents the rate of change (%) with the pain threshold before the onset of pain being 100%.
  • the white circle mark ( ⁇ ) in Fig. 2 indicates the case of no application, the black circle mark ( ⁇ ) indicates the case of 1% indomethacin, and the white triangle mark ( ⁇ ) indicates the case of 2% salty calp mouth-um. Show.
  • Shio Calp Mouth-um showed a fast-acting analgesic action similar to that of indomethacin.
  • the right hind paw volume before inflammation was measured using 8-week-old Wistar male rats. Subsequently, 0.1 ml of 1% strength ragenin solution dissolved in physiological saline is subcutaneously applied to the animal's right hind paw. Inflammation was induced by administration, and then the foot volume on the inflammation-inducing side was measured from 60 minutes at 15-minute intervals and from 1 hour to 5 hours at 1-hour intervals. The test substance was dissolved in a solution of isopropanol and water mixed at a ratio of 7: 3 and applied to the inflammation-inducing foot 30 minutes before the inflammation was induced.
  • test substance was carried out by calculating the edema volume at each hour from the difference in foot volume before and after the inflammation was induced, and calculating the area under the hour-one edema volume curve (AUC) and comparing it with the non-application group.
  • AUC hour-one edema volume curve
  • the pain threshold (Pre) of the right hind paw before pain induction was measured by the Randall Cerit method using 5-week-old male Wistar rats. Subsequently, 0.1 mL of 20% brewer's yeast solution suspended in physiological saline was subcutaneously administered to the right hind paw of the animal to induce pain, and the pain threshold was measured over time. The test substance was dissolved in purified water and orally administered 3 hours after the onset of pain. The effect of the test substance was evaluated by the transition of the pain threshold after oral administration.
  • FIG. 6 shows the time (time) from the onset of pain, and the vertical axis shows the pain threshold (mmHg) at each measurement point.
  • the white circles ( ⁇ ) in Fig. 6 indicate the control group treated with purified water, the black circles ( ⁇ ) indicate the salty carpronium 3 OmgZkg, and the black triangles ( ⁇ ) indicate the salty carp mouth-um.
  • the 60 mgZkg administration group is shown, and the black square (country) indicates the case of the salted calp mouth 120 mgZkg administration group.
  • Shio Calp Mouth-um showed a significant analgesic effect on the control at all times when the pain threshold was measured.
  • loxoprofen which is known as an anti-inflammatory analgesic
  • the same result as that of the salty calp mouth-rum of the present invention was obtained.
  • the calp mouthpiece of the present invention has the same kind of analgesic effect as known loxoprofen.
  • the right hind paw volume before inflammation was measured using 8-week-old Wistar male rats. Subsequently, 0.1 mL of a 1% strength ragenin solution dissolved in physiological saline is administered subcutaneously to the right hind footpad of the animal to cause inflammation. After 30 minutes and 1 hour, from 1 hour to 5 hours later The foot volume on the inflammation-inducing side was measured at 1 hour intervals.
  • the test substance was dissolved in purified water and administered orally 30 minutes before the inflammation occurred. The action of the test substance was carried out by calculating the edema volume for each hour, and calculating the area under the time edema volume curve (AUC) and comparing with the purified water administration group.
  • the anti-inflammatory effect of the test substance was shown by the change in edema volume at each measurement point in 5 patients in each group.
  • the results are shown in FIG.
  • the horizontal axis in Fig. 7 shows the time (hours) that causes inflammation, and the horizontal axis shows the edema volume (mL).
  • the white circles ( ⁇ ) in Fig. 7 indicate the purified water administration group as the control group, and the black circles ( ⁇ ) indicate the case of the salt-calp mouth-mu 120mgZkg administration group.
  • the salty calp mouth-um showed a significant anti-inflammatory effect on the control mouth at all times when the foot volume was measured.
  • the AUC from 1 hour to 1 hour and from 1 hour to 5 hours after the onset of inflammation was determined, and the inhibition rate of salted calpe mouthrum at each dose relative to the control was calculated.
  • the results are shown in Fig. 8.
  • the horizontal axis of FIG. 8 shows the dose (mgZkg p. O.), And the vertical axis shows the AUC suppression rate (%).
  • the white circles in FIG. 8 indicate the case of 0 to 1 hour after the administration of force ragenin, and the black circles indicate 1 to 5 hours later. From these results, it was found that salted calpe mouth-mud showed a dose-dependent anti-inflammatory effect even at 30 to 120 mgZkg even in oral administration, and the effect was strongly observed in the early stage of inflammation. .
  • loxoprofen which is known as an anti-inflammatory analgesic
  • results similar to those of the salted-carp mouthpiece of the present invention were obtained.
  • the calp mouthpiece of the present invention has the same kind of anti-inflammatory action as known loxoprofen.
  • the first component, the second component, and the third component are produced according to the formulation shown below.
  • an anti-inflammatory analgesic agent characterized by containing a calp mouth-um salt is provided, and can be used in the pharmaceutical industry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un agent analgésique anti-inflammatoire qui présente une excellente innocuité ainsi qu’un excellent effet anti-inflammatoire et/ ou effet analgésique. L’invention concerne un agent analgésique anti-inflammatoire comprenant un sel de carpronium (sel de 3-(méthoxycarbonylpropyl)triméthyl ammonium; un procédé pour le traitement /la prévention d’une inflammation et/ou d’une douleur au moyen de l’agent analgésique ; et l’utilisation d’un sel de carpronium pour la préparation de l’agent analgésique anti-inflammatoire.
PCT/JP2006/313718 2005-07-28 2006-07-11 Agent analgésique anti-inflammatoire WO2007013290A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007528401A JPWO2007013290A1 (ja) 2005-07-28 2006-07-11 抗炎症鎮痛剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005-219279 2005-07-28
JP2005-219280 2005-07-28
JP2005219279 2005-07-28
JP2005219280 2005-07-28

Publications (1)

Publication Number Publication Date
WO2007013290A1 true WO2007013290A1 (fr) 2007-02-01

Family

ID=37683191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/313718 WO2007013290A1 (fr) 2005-07-28 2006-07-11 Agent analgésique anti-inflammatoire

Country Status (3)

Country Link
JP (1) JPWO2007013290A1 (fr)
TW (1) TW200726465A (fr)
WO (1) WO2007013290A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5632415A (en) * 1979-08-27 1981-04-01 Yakurigaku Chuo Kenkyusho:Kk Remedy for dermatosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5632415A (en) * 1979-08-27 1981-04-01 Yakurigaku Chuo Kenkyusho:Kk Remedy for dermatosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KITA Y. ET AL.: "Kyusei Shigekisei Sesshoku Hifuen ni Zokuhatsu shita to Omowareru Zento Datsumo", HIFU, vol. 33, no. 2, 1991, pages 137 - 142, XP003007656 *
TAKAYASU S. ET AL.: "Enkei Datsumosho", POPULAR MEDICINE, no. 198, 1998, pages 12 - 16, XP003007655 *
ZAIDAN HOJIN NIPPON IYAKU JOHO CENTER: "Iryoyaku Nippon Iyakuhinshu 2004", vol. 27TH ED., 2004, pages: 593 - 594, XP003007654 *

Also Published As

Publication number Publication date
TW200726465A (en) 2007-07-16
JPWO2007013290A1 (ja) 2009-02-05

Similar Documents

Publication Publication Date Title
US20170035716A1 (en) Method of using solabegron
JP6441267B2 (ja) 過活動膀胱を治療するためのβ−３アドレナリン受容体アゴニストおよびムスカリン受容体アンタゴニストの組み合わせ
JP2000500449A (ja) 一酸化二窒素を含む鎮痛剤、抗炎症剤、および抗発熱剤のための投与媒体とそれらの医薬組成物
EP2037900A2 (fr) Traitement de l'excès de production de sébum
AU2019203694A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
CN114423439A (zh) Nmn用于预防和/或治疗疼痛的用途及相应组合物
DK3000466T3 (en) INHIBITOR FOR RETINOCHOROIDAL DISEASES
WO2008025543A1 (fr) Compositions pharmaceutiques destinées au traitement des infections fongiques
WO2016004056A1 (fr) Combinaisons pharmaceutiques
JP2021526554A (ja) 肛門直腸疾患の治療のための局所的なアムロジピン塩
EP2811989A1 (fr) Combinaison d'antagonistes des récepteurs muscariniques et d'agonistes de l'adrénorécepteur bêta -3 pour le traitement de la vessie hyperactive
US20170319519A1 (en) Combination for the treatment of conditions involving muscular pain
JP2008143856A (ja) 非ステロイド系抗炎症剤配合医薬
EP3801546A1 (fr) Procédé de traitement de la douleur ou de la cystite interstitielle à l'aide d'un composé indolique
WO2007013290A1 (fr) Agent analgésique anti-inflammatoire
CN114650827A (zh) 烟酰胺单核苷酸(nmn)用于预防和/或治疗类风湿性关节炎的用途和相应的组合物
JP2021512065A (ja) 三叉神経疼痛の予防及び治療のためのｎｅｐ及びａｐｎ阻害薬の形態である、ジスルファニル基を含んだアミノ酸誘導体
JP2006506377A (ja) テナトプラゾール及びヒスタミンｈ２受容体拮抗剤を組み合わせた医薬組成物
WO2007000970A1 (fr) Agent thérapeutique contre la douleur
UA146303U (uk) Спосіб симптоматичного лікування болю
JP2007204374A (ja) 解熱剤
CN114845722A (zh) 化合物在预防和/或治疗强直性脊柱炎中的应用和相应的组合物
TW202339711A (zh) 預防或治療心血管疾病的高穿透性的阿司匹靈和其他非類固醇抗發炎藥的前藥
UA146735U (uk) Фармацевтичний препарат для лікування болю та запалення
CN115715191A (zh) 排尿症状治疗剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007528401

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06780940

Country of ref document: EP

Kind code of ref document: A1